Human Genome Sciences Inc.
14200 Shady Grove Road
Rockville,
MD 20850-7464
United States - Map
Phone: 301-309-8504
Fax: 301-309-8512
Web Site: http://www.hgsi.com
| Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The companys clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. H. Thomas Watkins , 56
Chief Exec. Officer, Pres |
$
1.15M |
$
0 | Mr. Timothy C. Barabe , 55
Chief Financial Officer, Principal Accounting Officer and Sr. VP |
$
491.00K |
$
0 | Dr. James H. Davis Ph.D., JD, 57
Exec. VP, Sec. and Gen. Counsel |
$
608.00K |
$
0 | Dr. David C. Stump M.D., 59
Exec. VP of R&D |
$
667.00K |
$
0 | Mr. Barry A. Labinger , 45
Chief Commercial Officer, Exec. VP and Member of Management Committee |
$
664.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
